Get the Stockscreener App
98.61
2.93%
2.805
Pre-market:
94.21
-4.395
-4.46%
Insmed Inc stock is traded at $98.61, with a volume of 4.23M.
It is up +2.93% in the last 24 hours and down -7.19% over the past month.
Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from the United States from the sale of its commercial products.
See More
Previous Close:
$95.80
Open:
$95.82
24h Volume:
4.23M
Relative Volume:
1.17
Market Cap:
$21.37B
Revenue:
$819.56M
Net Income/Loss:
$-1.18B
P/E Ratio:
-17.17
EPS:
-5.7434
Net Cash Flow:
$-951.64M
1W Performance:
+1.17%
1M Performance:
-7.19%
6M Performance:
-43.90%
1Y Performance:
-3.97%
1-Day Range:
$95.27
$99.88
1-Week Range:
$93.92
$100.25
52-Week Range:
$90.39
$212.75
Insmed Inc Stock (INSM) Company Profile
Name
Insmed Inc
Sector
Industry
Phone
908-977-9900
Address
700 US HIGHWAY 202/206, BRIDGEWATER, NJ
Compare INSM vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INSM
Insmed Inc
|
98.61 | 20.76B | 819.56M | -1.18B | -951.64M | -5.7434 |
VRTX
Vertex Pharmaceuticals Inc
|
466.79 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
612.50 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
903.75 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
286.41 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
165.81 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Insmed Inc Stock (INSM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-10-26 | Initiated | Raymond James | Outperform |
| Mar-30-26 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Mar-16-26 | Resumed | Jefferies | Buy |
| Jan-28-26 | Initiated | Barclays | Overweight |
| Jan-23-26 | Initiated | Roth Capital | Buy |
| Dec-19-25 | Resumed | Truist | Buy |
| Dec-04-25 | Initiated | Rothschild & Co Redburn | Buy |
| Oct-28-25 | Resumed | Cantor Fitzgerald | Overweight |
| Oct-20-25 | Initiated | Wells Fargo | Overweight |
| Aug-20-25 | Initiated | William Blair | Outperform |
| Aug-13-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| May-13-25 | Initiated | Jefferies | Buy |
| Feb-25-25 | Initiated | RBC Capital Mkts | Outperform |
| Apr-23-24 | Initiated | Truist | Buy |
| Feb-15-24 | Initiated | Wolfe Research | Outperform |
| Dec-08-23 | Initiated | Wells Fargo | Overweight |
| Nov-20-23 | Resumed | JP Morgan | Overweight |
| Jul-26-23 | Initiated | Guggenheim | Buy |
| Dec-09-22 | Initiated | Mizuho | Buy |
| Dec-07-22 | Initiated | Barclays | Overweight |
| Nov-18-22 | Initiated | BofA Securities | Buy |
| Apr-27-22 | Initiated | Goldman | Buy |
| Dec-06-21 | Initiated | JP Morgan | Overweight |
| Oct-19-21 | Resumed | Monness Crespi & Hardt | Buy |
| Oct-19-21 | Resumed | Morgan Stanley | Overweight |
| Oct-08-21 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Dec-17-20 | Initiated | Berenberg | Buy |
| Oct-12-20 | Resumed | Stifel | Buy |
| Sep-03-19 | Initiated | Goldman | Buy |
| Apr-09-19 | Reiterated | H.C. Wainwright | Buy |
| Feb-15-19 | Upgrade | JMP Securities | Mkt Perform → Mkt Outperform |
| Jan-17-19 | Upgrade | Goldman | Neutral → Buy |
| Jan-02-19 | Initiated | Canaccord Genuity | Buy |
| Aug-06-18 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Jul-23-18 | Initiated | Goldman | Neutral |
| Apr-23-18 | Upgrade | Credit Suisse | Neutral → Outperform |
| Mar-21-18 | Initiated | Morgan Stanley | Overweight |
| Jan-18-18 | Initiated | Credit Suisse | Neutral |
| Sep-05-17 | Reiterated | Evercore ISI | Outperform |
| Aug-17-17 | Initiated | Evercore ISI | Outperform |
| Jul-11-17 | Initiated | Robert W. Baird | Outperform |
| Mar-15-16 | Initiated | Stifel | Buy |
| Nov-09-15 | Downgrade | UBS | Buy → Neutral |
| Oct-06-15 | Reiterated | H.C. Wainwright | Buy |
| Jun-09-15 | Initiated | Citigroup | Neutral |
| Mar-26-14 | Reiterated | HC Wainwright | Buy |
View All
Insmed Inc Stock (INSM) Latest News
Should Insmed’s (INSM) NASDAQ-100 Exit and TPIP Focus Require Action From Investors? - Yahoo Finance
Form 144 INSMED INC For: 22 June By Investing.com - Investing.com Canada
Michael Smith files Form 144 listing multiple INSM share sales (INSM) - Stock Titan
INSM Maintained by Evercore ISI Group -- Price Target Lowered to $160 - GuruFocus
Is Insmed (INSM) One of the Most Promising Healthcare Stocks After Cantor Fitzgerald’s Target Raise? - Yahoo Finance
Insmed’s New Lung Disease Study Data A Win For Company, Says Analyst - Stocktwits
INSM, FSLR, APTV: Dreaded Death Cross Has Formed On These Stocks — What It Means For Investors - Stocktwits
INSM Stock Dips In Extended Trading After Experimental Skin Disease Drug Fails In Study - Stocktwits
What's Driving Insmed's Recent Volatility - Kavout
3 US Pharmaceutical Stocks With Cash Flow And Pricing Risk - Sahm
Insmed Stockanalyst coverage and sector comparison at week’s end - AD HOC NEWS
Insmed Inc (MIL:1INSM) Stock Price, Trades & News - GuruFocus
InvestingPro’s Fair Value spotted Insmed’s 44% drop before it happened By Investing.com - Investing.com
Insmed Incorporated(NasdaqGS: INSM) dropped from NASDAQ-100 Index - marketscreener.com
Insmed slips as investors weigh recent analyst caution and launch expectations - Quiver Quantitative
Top Insmed (INSM) Competitors 2026 - MarketBeat
Insmed Inc (INSM) Valuation: PE, PB & Fair Value Analysis - TradingKey
Insmed Inc (INSM) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Insmed Inc (INSM) Institutional Confidence - TradingKey
Insmed Inc (INSM) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Insmed Inc (INSM) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Insmed Inc (INSM) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Insmed Inc (INSM) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Insmed Inc (INSM) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Insmed Inc (INSM) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
TD Cowen Maintains Insmed(INSM.US) With Buy Rating, Maintains Target Price $243 - Moomoo
Mizuho cuts Insmed stock price target on volatility concerns - Investing.com UK
Mizuho cuts Insmed stock price target on volatility concerns By Investing.com - Investing.com Nigeria
Exome Asset Management LLC's Insmed Inc(INSM) Holding History - GuruFocus
Insmed (INSM) Sees Price Target Reduction Amid Market Sentiment Shift - GuruFocus
Monashee Investment Management LLC Acquires Shares of 50,000 Insmed, Inc. $INSM - MarketBeat
A Blueprint For Addressing Underserved Patient Populations - Clinical Leader
Nasdaq-100 Index® June 2026 Quarterly Changes - GlobeNewswire Inc.
BofA Securities Maintains Insmed(INSM.US) With Buy Rating, Maintains Target Price $214 - Moomoo
Insmed stock hits 52-week low at 90.85 USD By Investing.com - Investing.com Nigeria
Daily Brief Health Care: Laurus Labs, Ascendis Pharma, GSK , Incyte Corp, Insmed Inc, Johnson & Johnson, Kardigan, LogicMark, Parabilis Medicines, Solventum and more - Smartkarma
Insmed slides 7.9% as risk-off tape collides with pipeline-focused positioning ahead of TPIP data - Quiver Quantitative
[Form 4] INSMED Inc Insider Trading Activity - Stock Titan
Insmed stock hits 52-week low at 90.85 USD - Investing.com
Stock Traders Purchase High Volume of Call Options on Insmed (NASDAQ:INSM) - MarketBeat
Cantor Fitzgerald reiterates Insmed stock rating on TPIP data outlook - Investing.com UK
Cantor Fitzgerald reiterates Insmed stock rating on TPIP data outlook By Investing.com - Investing.com Australia
GW&K Investment Management LLC Reduces Position in Insmed, Inc. $INSM - MarketBeat
Axiom Investors LLC DE Has $44.53 Million Position in Insmed, Inc. $INSM - MarketBeat
Insmed Inc stock (US4576693075): pipeline update and growth story in rare diseases - AD HOC NEWS
INSM: Brensocatib’s stellar launch and expanding pipeline set the stage for sustained growth - TradingView
Insmed Inc at Goldman Sachs Healthcare Conference Transcript - GuruFocus
INSM Maintained by JP Morgan -- Price Target Lowered to $179 - GuruFocus
Insmed (INSM) Remains a Strong Buy Despite Recent Stock Decline - GuruFocus
William Lewis files Form 144 — INSM insider sale notice (INSM) - Stock Titan
Insmed Is Maintained at Overweight by JP Morgan - Moomoo
Insmed Inc Stock (INSM) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.57%
1.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):